MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers
Gastroenterological cancers are the most common cancers categorized by systems and are estimated to comprise 18.4% of all cancers in the United States in 2017. Gastroenterological cancers are estimated to contribute 26.2% of cancer-related death in 2017. Gastroenterological cancers are characterized...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2018/9740357 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555884018925568 |
|---|---|
| author | Yixin Yang Christopher Alderman Ayoub Sehlaoui Yuan Xiao Wei Wang |
| author_facet | Yixin Yang Christopher Alderman Ayoub Sehlaoui Yuan Xiao Wei Wang |
| author_sort | Yixin Yang |
| collection | DOAJ |
| description | Gastroenterological cancers are the most common cancers categorized by systems and are estimated to comprise 18.4% of all cancers in the United States in 2017. Gastroenterological cancers are estimated to contribute 26.2% of cancer-related death in 2017. Gastroenterological cancers are characterized by late diagnosis, metastasis, high recurrence, and being refractory to current therapies. Since the current targeted therapies provide limited benefit to the overall response and survival, there is an urgent need for developing novel therapeutic strategy to improve the outcome of gastroenterological cancers. Immunotherapy has been developed and underwent clinical trials, but displayed limited therapeutic benefit. Since aberrant expressions of miRNAs are found in gastroenterological cancers and miRNAs have been shown to regulate antitumor immunity, the combination therapy combining the traditional antibody-based immunotherapy and novel miRNA-based immunotherapy is promising for achieving clinical success. This review summarizes the current knowledge about the miRNAs and long noncoding RNAs that exhibit immunoregulatory roles in gastroenterological cancers and precancerous diseases of digestive system, as well as the miRNA-based clinical trials for gastroenterological cancers. This review also analyzes the ongoing challenge of identifying appropriate therapy candidates for complex and dynamic tumor microenvironment, ensuring efficient and targeted delivery to specific cancer tissues, and developing strategy for avoiding off-target effect. |
| format | Article |
| id | doaj-art-d6a8c477926c470786102f576d907d87 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-d6a8c477926c470786102f576d907d872025-02-03T05:47:00ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972018-01-01201810.1155/2018/97403579740357MicroRNAs as Immunotherapy Targets for Treating Gastroenterological CancersYixin Yang0Christopher Alderman1Ayoub Sehlaoui2Yuan Xiao3Wei Wang4College of Natural, Applied and Health Sciences, Kean University, 100 Morris Avenue, Union, NJ 07083, USASchool of Medicine, University of Colorado, 13001 E 17th Pl, Aurora, CO 80045, USADepartment of Biological Sciences, Emporia State University, 1 Kellogg Circle, Emporia, KS 66801, USADepartment of Biological Sciences, Emporia State University, 1 Kellogg Circle, Emporia, KS 66801, USADepartment of Thoracic Surgery III, Cancer Hospital of China Medical University, No. 44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning 110042, ChinaGastroenterological cancers are the most common cancers categorized by systems and are estimated to comprise 18.4% of all cancers in the United States in 2017. Gastroenterological cancers are estimated to contribute 26.2% of cancer-related death in 2017. Gastroenterological cancers are characterized by late diagnosis, metastasis, high recurrence, and being refractory to current therapies. Since the current targeted therapies provide limited benefit to the overall response and survival, there is an urgent need for developing novel therapeutic strategy to improve the outcome of gastroenterological cancers. Immunotherapy has been developed and underwent clinical trials, but displayed limited therapeutic benefit. Since aberrant expressions of miRNAs are found in gastroenterological cancers and miRNAs have been shown to regulate antitumor immunity, the combination therapy combining the traditional antibody-based immunotherapy and novel miRNA-based immunotherapy is promising for achieving clinical success. This review summarizes the current knowledge about the miRNAs and long noncoding RNAs that exhibit immunoregulatory roles in gastroenterological cancers and precancerous diseases of digestive system, as well as the miRNA-based clinical trials for gastroenterological cancers. This review also analyzes the ongoing challenge of identifying appropriate therapy candidates for complex and dynamic tumor microenvironment, ensuring efficient and targeted delivery to specific cancer tissues, and developing strategy for avoiding off-target effect.http://dx.doi.org/10.1155/2018/9740357 |
| spellingShingle | Yixin Yang Christopher Alderman Ayoub Sehlaoui Yuan Xiao Wei Wang MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers Canadian Journal of Gastroenterology and Hepatology |
| title | MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers |
| title_full | MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers |
| title_fullStr | MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers |
| title_full_unstemmed | MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers |
| title_short | MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers |
| title_sort | micrornas as immunotherapy targets for treating gastroenterological cancers |
| url | http://dx.doi.org/10.1155/2018/9740357 |
| work_keys_str_mv | AT yixinyang micrornasasimmunotherapytargetsfortreatinggastroenterologicalcancers AT christopheralderman micrornasasimmunotherapytargetsfortreatinggastroenterologicalcancers AT ayoubsehlaoui micrornasasimmunotherapytargetsfortreatinggastroenterologicalcancers AT yuanxiao micrornasasimmunotherapytargetsfortreatinggastroenterologicalcancers AT weiwang micrornasasimmunotherapytargetsfortreatinggastroenterologicalcancers |